|Bid||50.80 x 200|
|Ask||50.81 x 2400|
|Day's Range||50.62 - 51.00|
|52 Week Range||37.38 - 51.13|
|PE Ratio (TTM)||52.81|
|Earnings Date||Oct 17, 2017 - Oct 23, 2017|
|Dividend & Yield||1.06 (2.08%)|
|1y Target Est||55.06|
In 2Q17, Abbott Laboratories' (ABT) Medical Devices segment reported a strong performance once again, registering a YoY sales growth of 89.2%.
On July 20, 2017, Abbott Laboratories (ABT) released its 2Q17 earnings. That day, ABT stock rose more than 4.0% from its closing price of $49.40 on July 19, 2017.
When it completes its $5.3 billion acquisition of Waltham-based Alere later this year, Abbott Laboratories will be getting one of the world’s largest makers of point-of-care diagnostic tests, a fast-growing sector. Thanks to antitrust rules, though, Abbott (ABT) will be taking on a slimmed-down version of Alere (ALR) by the end of September. Back in January, Illinois-based Abbott agreed to divest three Alere business units that make competing products in order to secure the approval of European Union antitrust regulators.